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ABSTRACT 
 
Background: INA-CBG is an abbreviation of Indonesia Case Base Groups which 
is an application that the hospital uses to make claims to the government. For 
health service payments under the Indonesian National Health Insurance (JKN) 
scheme, health-BPJS as the JKN implementer makes payments to the hospitals 
based on INA-CBG rates. However, this has not been effective because INA rates 
of CBG have the potential to cause loss to hospitals. This study aimed to estimate 
the difference between INA-CBG reimbursement and medical cost for patients 
with chronic renal disease in Kasih Ibu Hospital, Surakarta, and analyze factors 
affecting the difference. 
Subjects and Method: This was a cross sectional study conducted at Kasih Ibu 
Hospital Surakarta, Central Java, in August to October 2017. With a total of 231 
subjects sample which was selected by using proportional random sampling. The 
dependent variable was the difference between INA-CBG reimbursement and 
medical cost. The independent variables were length of stay, type of class, medical 
treatment/ surgery, ICU treatment, and medication use. The data were analyzed 
using amultiple linearregression. 
Results: INA-CBG reimbursement (mean= Rp 6,120,000; SD= Rp 2,330,000) 
paid by BPJS Kesehatan was lower than actual hospital’s medical care cost 
(mean= Rp 7,070,000; SD= Rp 4,650,000). Factors profitable for hospitals were 
medical treatments/ surgery (b= 0.032; p= 0.552). Factors that inflicted financial 
loss were class 1 care (b= -0.104; p= 0.094), class 2 care (b= -0.033; p= 0.590) 
compared to class 3 care, length of stay (b= -0.541; p<0.001), medication use in 
accordance with national formulation (b= -0.183; p= 0.008) and the use of ICU 
(b= -0.045; p= 0.543). Patients who upgraded the class type (mean= Rp 
5,526,074; SD= Rp 1,449,621) was higher than hospital’s medical cost for class 2 
(mean= Rp 3,933,767; SD= Rp 1,887,900). 
Conclusion: Mean of INA-CBG reimbursement on inpatient care of chronic 
renal disease is lower than the mean of hospital’s medical care cost. Length of 
stay and doctors’ compliance in using national medication formulation are 
important determinants to increase medical care cost. Hospital obtains profit 
from patients who upgrade type of class.  
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